China NMPA Inspection - Guangxi Bagen Liuzhu Pharmaceutical Technology Co., Ltd. - September 14, 2020

On September 14, 2020, the Guangxi Zhuang Autonomous Region Drug Administration announced findings from unannounced inspections of cosmetics manufacturers conducted in August. These inspections, guided by the "Key Points for Cosmetic Production License Inspection," aimed to enhance regulatory oversight.

Guangxi Bagen Liuzhu Pharmaceutical Technology Co., Ltd. (August 4-5) was cited for improper storage of flammable materials and inadequate organization of raw and packaging materials, which lacked batch storage, designated locations, and supplier/batch labeling.

Guangxi Chashi Family Camellia Seed Co., Ltd. (August 3-4) lacked a dedicated, clearly labeled area for non-conforming products and failed to properly separate its raw and packaging material warehouses from the general plant raw material area.

Guangxi Wanhao Biotechnology Co., Ltd. (August 6-7) faced issues with its quality manager not fully fulfilling duties and inconsistencies between equipment disinfection periods and their cleaning/disinfection system.

Guangxi Zhuangmei Biotechnology Co., Ltd. (August 5-6) had several deficiencies: failure to verify/calibrate measuring instruments per national requirements, an incomplete non-conforming product management system lacking defined procedures/timelines, and the absence of an annual internal audit plan or conducted internal audits.

All four companies have been mandated to implement rectification within a specified period.